☰

Jane E. Cavanaugh - Publications

Affiliations: 
Pharmacology Duquesne University, Pittsburgh, PA, United States 
Area:
Aging, Pharmacology, Neuroscience Biology
Tree Info Grants Similar researchers PubMed Report error

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Matossian MD, Hoang VT, Burks HE, La J, Elliott S, Brock C, Rusch DB, Buechlein A, Nephew KP, Bhatt A, Cavanaugh JE, Flaherty PT, Collins-Burow BM, Burow ME. Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer. Oncoscience. 8: 64-71. PMID 34026925 DOI: 10.18632/oncoscience.535  0.307
2021 Hoang VT, Matossian MD, La J, Hoang K, Ucar DA, Elliott S, Burks HE, Wright TD, Patel S, Bhatt A, Phamduy T, Chrisey D, Buechlein A, Rusch DB, Nephew KP, ... ... Cavanaugh JE, et al. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation. Journal of Cellular Biochemistry. PMID 33876843 DOI: 10.1002/jcb.29916  0.332
2021 Bhatt AB, Wright TD, Barnes V, Chakrabarty S, Matossian MD, Lexner E, Ucar DA, Miele L, Flaherty PT, Burow ME, Cavanaugh JE. Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. Translational Oncology. 14: 101046. PMID 33761370 DOI: 10.1016/j.tranon.2021.101046  0.32
2020 Hoang VT, Matossian MD, Ucar DA, Elliott S, La J, Wright MK, Burks HE, Perles A, Hossain F, King CT, Browning VE, Bursavich J, Fang F, Del Valle L, Bhatt AB, ... Cavanaugh JE, et al. ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. Frontiers in Oncology. 10: 1164. PMID 32850332 DOI: 10.3389/Fonc.2020.01164  0.387
2020 Bhatt A, Wright T, Barnes V, Chakrabarty S, Flaherty P, Burow M, Cavanaugh J. Abstract 5042: Targeting the ERK5 and ERK1/2 pathways simultaneously induces mesenchymal to epithelial transition in TNBC Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5042  0.356
2019 Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. Journal of Cellular Biochemistry. PMID 31464004 DOI: 10.1002/Jcb.29350  0.464
2019 Bhatt AB, Gupta M, Hoang VT, Chakrabarty S, Wright TD, Elliot S, Chopra IK, Monlish D, Anna K, Burow ME, Cavanaugh JE, Flaherty PT. Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer. Frontiers in Oncology. 9: 672. PMID 31417863 DOI: 10.3389/Fonc.2019.00672  0.344
2019 Bhatt A, Wright T, Anna K, Gupta M, Chakrabarty S, Flaherty P, Hoang V, Burow M, Cavanaugh J. Abstract P5-08-07: Study of diphenylamine analogs as inducers of mesenchymal to epithelial transition in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-08-07  0.306
2019 Ucar D, Matossian, Hoang-Barnes V, Hossain F, Gupta M, Burks H, Wright T, Cavanaugh J, Flaherty P, Burow M, Miele L. Abstract P2-03-04: A novel druggable target upstream of Notch: MEK5/ERK5 signaling regulates Jagged-1 and Notch1 expression in triple negative breast cancer stem cells Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-03-04  0.417
2019 Bhatt AB, Wright TD, Anna K, Gupta M, Chakrabarty S, Hoang V, Burow M, Flaherty PT, Cavanaugh JE. Abstract 1879: Novel diphenylamine analogs induce mesenchymal to epithelial transition and enhance the sensitivity of breast cancer cells to conventional chemotherapeutic agents Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1879  0.318
2019 Bhatt AB, Wright TD, Patel S, Chakrabarty S, Barnes V, Burow M, Flaherty PT, Cavanaugh J. Abstract B078: Inhibition of the MAPK pathways enhances the sensitivity of triple negative breast cancer cells to chemotherapeutic drugs Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B078  0.437
2018 Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE. Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways. Bioorganic & Medicinal Chemistry Letters. PMID 29803729 DOI: 10.1016/J.Bmcl.2018.05.029  0.361
2018 Ucar-Bilyeu DA, Matossian MD, Barnes VH, Hossain FM, Gupta M, Burks HE, Wright TD, Cavanaugh J, Flaherty P, Burow ME, Miele L. Abstract 967: Targeting notch one notch above Cancer Research. 78: 967-967. DOI: 10.1158/1538-7445.Am2018-967  0.4
2018 Hasan M, Marzouk MA, Adhikari S, Wright T, Miller B, Peckich B, Yingling S, Stratford R, Zlotos D, Cavanaugh J, Witt-Enderby P. Abstract 3915: Melatonin-tamoxifen hybrid ligands and their effects on breast cancer Cancer Research. 78: 3915-3915. DOI: 10.1158/1538-7445.Am2018-3915  0.312
2018 Wright TD, Raybuck C, Gartland N, Wendekier K, Monlish D, Chakrabarty S, Flaherty PT, Burow ME, Cavanaugh JE. Abstract 2392: Evaluation of synergistic PI3K/Akt and MEK5/ERK5 inhibition in triple-negative breast cancer Cancer Research. 78: 2392-2392. DOI: 10.1158/1538-7445.Am2018-2392  0.448
2017 Allen EN, Potdar S, Tapias V, Parmar M, Mizuno CS, Rimando A, Cavanaugh JE. Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1/2-dependent mechanism. The Journal of Nutritional Biochemistry. 54: 77-86. PMID 29268122 DOI: 10.1016/J.Jnutbio.2017.10.015  0.728
2017 Potdar S, Parmar MS, Ray SD, Cavanaugh JE. Protective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells. Archives of Toxicology. PMID 28980048 DOI: 10.1007/S00204-017-2073-Z  0.721
2017 Sadler KE, Gartland NM, Cavanaugh JE, Kolber BJ. Central amygdala activation of extracellular signal-regulated kinase 1 and age-dependent changes in inflammatory pain sensitivity in mice. Neurobiology of Aging. PMID 28526294 DOI: 10.1016/J.Neurobiolaging.2017.04.010  0.329
2017 Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME. MEK5-ERK5 Signaling in Cancer: Implications for Targeted Therapy. Cancer Letters. PMID 28153789 DOI: 10.1016/J.Canlet.2017.01.034  0.399
2017 Wright T, Raybuck C, Wendekier K, Cavanaugh J. Abstract P3-07-19: Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-07-19  0.393
2017 Wright TD, Hasan M, Witt-Enderby P, Cavanaugh J. Abstract 2365: Dual inhibition of the PI3k/Akt and MEK5/ERK5 pathways in tamoxifen resistant breast cancer Cancer Research. 77: 2365-2365. DOI: 10.1158/1538-7445.Am2017-2365  0.402
2016 Wright T, Raybuck C, Wendekier K, Cavanaugh JE. Abstract 182: Dual inhibition of the MEK5 and PI3K pathways most effectively reduces proliferation and migration in triple negative breast cancer cells Cancer Research. 76: 182-182. DOI: 10.1158/1538-7445.Am2016-182  0.458
2016 Hoang VT, Elliott S, Martin EC, Rhodes LV, Burks HE, Matossian M, Chakrabarty S, Monlish D, Phamduy TB, Curley L, Anbalagan M, Rowan BG, Chrisey D, Cavanaugh JE, Flaherty PT, et al. Abstract 1596: Induction of mesenchymal-to-epithelial transition through pan-MEK inhibition in triple-negative breast cancer Cancer Research. 76: 1596-1596. DOI: 10.1158/1538-7445.Am2016-1596  0.444
2016 Flaherty PT, Shah D, Gupta M, Wright T, Cavanaugh JE, Burow ME. Abstract 1337: Exploration of 2-aryl fused thiophene analogs as selective inhibitors of MEK5 Cancer Research. 76: 1337-1337. DOI: 10.1158/1538-7445.Am2016-1337  0.38
2015 Parmar MS, Jaumotte JD, Zigmond MJ, Cavanaugh JE. ERK1, 2, and 5 expression and activation in dopaminergic brain regions during postnatal development. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 46: 44-50. PMID 26363522 DOI: 10.1016/J.Ijdevneu.2015.06.009  0.733
2014 Rose KM, Parmar MS, Cavanaugh JE. Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure. Brain Research. 1573: 37-43. PMID 24863468 DOI: 10.1016/J.Brainres.2014.05.028  0.691
2014 Allen EN, Cavanaugh JE. Loss of motor coordination in an aging mouse model. Behavioural Brain Research. 267: 119-25. PMID 24675158 DOI: 10.1016/J.Bbr.2014.03.032  0.333
2014 Parmar MS, Jaumotte JD, Wyrostek SL, Zigmond MJ, Cavanaugh JE. Role of ERK1, 2, and 5 in dopamine neuron survival during aging. Neurobiology of Aging. 35: 669-79. PMID 24411019 DOI: 10.1016/J.Neurobiolaging.2013.09.031  0.738
2014 Hoang VT, Elliott S, Martin EC, Rhodes LV, Segar HC, Burks H, Chakrabarty S, Monlish D, Phamduy TB, Chrisey D, Cavanaugh JE, Flaherty P, Collins-Burow BM, Burow ME. Abstract 1052: Dual role of MEK1/2 and MEK5 in the reversal of epithelial-to-mesenchymal transition Cancer Research. 74: 1052-1052. DOI: 10.1158/1538-7445.Am2014-1052  0.458
2013 Cavanaugh JE, Monlish DA, Chakrabarty S, Qin S, Flaherty PT. Abstract 929: Caboxylic acid esters as inhibitors of the MEK1/2 and MEK5 signaling cascades. Cancer Research. 73: 929-929. DOI: 10.1158/1538-7445.Am2013-929  0.447
2012 Monlish DA, Cavanaugh JE. Abstract 2242: The MAPK and PI3K signaling pathways in breast cancer: Crosstalk mechanisms and the effect on cell proliferation Cancer Research. 72: 2242-2242. DOI: 10.1158/1538-7445.Am2012-2242  0.472
2010 Flaherty PT, Chopra I, Jain P, Monlish D, Cavanaugh J. Structure-activity relationships of benzimidazole-based selective inhibitors of the mitogen activated kinase-5 signaling pathway Bioorganic and Medicinal Chemistry. 18: 8054-8060. PMID 20965737 DOI: 10.1016/J.Bmc.2010.09.017  0.397
2010 Flaherty PT, Chopra I, Jain P, Yi S, Allen E, Cavanaugh J. Identification of benzimidazole-based inhibitors of the mitogen activated kinase-5 signaling pathway Bioorganic and Medicinal Chemistry Letters. 20: 2892-2896. PMID 20382528 DOI: 10.1016/J.Bmcl.2010.03.033  0.401
2010 Monlish D, Cavanaugh J. Abstract P2-07-05: Age-Related Changes in ERK5 Signaling and Crosstalk with ERK1/2 and PI3K in Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-07-05  0.493
2009 Monlish DA, Cavanaugh JE. Abstract B94: The roles of ERK1/2 and ERK5 in age‐related breast cancer proliferation Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B94  0.475
2008 Lin E, Cavanaugh JE, Leak RK, Perez RG, Zigmond MJ. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. Journal of Neuroscience Research. 86: 108-17. PMID 17847117 DOI: 10.1002/jnr.21478  0.352
2006 Cavanaugh JE, Jaumotte JD, Lakoski JM, Zigmond MJ. Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. Journal of Neuroscience Research. 84: 1367-75. PMID 16941494 DOI: 10.1002/jnr.21024  0.488
2004 Cavanaugh JE. Role of extracellular signal regulated kinase 5 in neuronal survival. European Journal of Biochemistry / Febs. 271: 2056-9. PMID 15153094 DOI: 10.1111/j.1432-1033.2004.04131.x  0.374
2003 Liu L, Cavanaugh JE, Wang Y, Sakagami H, Mao Z, Xia Z. ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons. Proceedings of the National Academy of Sciences of the United States of America. 100: 8532-7. PMID 12826611 DOI: 10.1073/Pnas.1332804100  0.38
Show low-probability matches.